H.I.G. BioVentures focuses on early to mid-stage life sciences companies. We are proud of our portfolio companies and the value they create for their patients, employees and other stakeholders. We invite you to visit each company.

"H.I.G. BioVentures has played a major role as one of the founding partners of our organization. Not only did the firm recognize the value of developing neuronal Nitric Oxide Synthase (nNOS) inhibitors for the treatment of neuropathic pain and migraine, they came to the table at the earliest stage and have continued to deliver unwavering support as we grow this company. The strategic direction provided by H.I.G. BioVentures has been an invaluable asset."

- John Andrews, President NeurAxon, Inc.